Literature DB >> 23953350

Lifetime direct medical costs of treating type 2 diabetes and diabetic complications.

Xiaohui Zhuo1, Ping Zhang, Thomas J Hoerger.   

Abstract

BACKGROUND: Lifetime direct medical cost of treating type 2 diabetes and diabetic complications in the U.S. is unknown.
PURPOSE: This study provides nationally representative estimates of lifetime direct medical costs of treating type 2 diabetes and diabetic complications in people newly diagnosed with type 2 diabetes, by gender and by age at diagnosis.
METHODS: A type 2 diabetes simulation model was used to simulate the disease progression and direct medical costs among a cohort of newly diagnosed type 2 diabetes patients. The study sample used for the simulation was based on data from the 2009-2010 National Health and Nutritional Examination Survey. The costs of treating type 2 diabetes and diabetic complications were derived from published literature. Annual medical costs were accumulated over the life span of type 2 diabetes to determine the lifetime medical costs. All costs were calculated from a healthcare system perspective, and expressed in 2012 dollars.
RESULTS: In men diagnosed with type 2 diabetes at ages 25-44 years, 45-54 years, 55-64 years, and ≥ 65 years, the lifetime direct medical costs of treating type 2 diabetes and diabetic complications were $124,700, $106,200, $84,000, and $54,700, respectively. In women, the costs were $130,800, $110,400, $85,500, and $56,600, respectively. The age-gender weighted average of the lifetime medical costs was $85,200, of which 53% was due to treating diabetic complications. The cost of managing macrovascular complications accounted for 57% of the total complication cost.
CONCLUSIONS: Over the lifetime, type 2 diabetes imposes a substantial economic burden on healthcare systems. Effective interventions that prevent or delay type 2 diabetes and diabetic complications might result in substantial long-term savings in healthcare costs. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23953350     DOI: 10.1016/j.amepre.2013.04.017

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  64 in total

1.  Adherence to diabetes guidelines for screening, physical activity and medication and onset of complications and death.

Authors:  Yiqun Chen; Frank A Sloan; Arseniy P Yashkin
Journal:  J Diabetes Complications       Date:  2015-07-09       Impact factor: 2.852

2.  Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.

Authors:  Matthew A Cavender; William B White; Yuyin Liu; Joseph M Massaro; Richard M Bergenstal; Cyrus R Mehta; Faiez Zannad; Simon Heller; William C Cushman; Christopher P Cannon
Journal:  Clin Cardiol       Date:  2018-08-16       Impact factor: 2.882

3.  Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.

Authors:  Sheriza N Baksh; Mara McAdams-DeMarco; Jodi B Segal; G Caleb Alexander
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-04-14       Impact factor: 2.890

4.  Reducing the prevalence of dysglycemia: is the time ripe to test the effectiveness of intervention in high-risk individuals with elevated 1 h post-load glucose levels?

Authors:  Michael Bergman; Ram Jagannathan; Martin Buysschaert; Jose Luis Medina; Mary Ann Sevick; Karin Katz; Brenda Dorcely; Jesse Roth; Angela Chetrit; Rachel Dankner
Journal:  Endocrine       Date:  2017-01-25       Impact factor: 3.633

5.  The Lifestyle Medicine Physician's Case to Self-Insured Employers: A Business Model for Physicians, a Bargain for Companies.

Authors:  Mahima Gulati; Mary Delaney
Journal:  Am J Lifestyle Med       Date:  2019-05-14

Review 6.  Diabetes self-management interventions for adults with type 2 diabetes living in rural areas: a systematic literature review.

Authors:  Morgan Griesemer Lepard; Alessandra L Joseph; April A Agne; Andrea L Cherrington
Journal:  Curr Diab Rep       Date:  2015-06       Impact factor: 4.810

7.  Direct and indirect costs associated to type 2 diabetes and its complications measured in a social security institution of Argentina.

Authors:  Jorge F Elgart; Santiago Asteazarán; Jorge L De La Fuente; Cecilia Camillucci; Jonathan B Brown; Juan José Gagliardino
Journal:  Int J Public Health       Date:  2014-09-05       Impact factor: 3.380

Review 8.  Global aetiology and epidemiology of type 2 diabetes mellitus and its complications.

Authors:  Yan Zheng; Sylvia H Ley; Frank B Hu
Journal:  Nat Rev Endocrinol       Date:  2017-12-08       Impact factor: 43.330

9.  Impact of chronic disease self-management programs on type 2 diabetes management in primary care.

Authors:  Samuel N Forjuoh; Marcia G Ory; Luohua Jiang; Ann M Vuong; Jane N Bolin
Journal:  World J Diabetes       Date:  2014-06-15

10.  Trajectory of Excess Medical Expenditures 10 Years Before and After Diabetes Diagnosis Among U.S. Adults Aged 25-64 Years, 2001-2013.

Authors:  Sundar S Shrestha; Ping Zhang; Israel A Hora; Edward W Gregg
Journal:  Diabetes Care       Date:  2018-11-19       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.